https://www.live-feeds.com/feed/novo-is-betting-on-its-next-chapter-as-eli-lilly-gains-more-ground-in-glp-1sContinuously updated, source-cited coverage. https://www.live-feeds.com/feed/novo-is-betting-on-its-next-chapter-as-eli-lilly-gains-more-ground-in-glp-1shttps://www.live-feeds.com/feed/novo-is-betting-on-its-next-chapter-as-eli-lilly-gains-more-ground-in-glp-1s#u86318Sun, 27 Sep 2026 15:47:25 +0000Novo Nordisk is betting on its next growth chapter as rival Eli Lilly gains more ground in the GLP-1 drug market. The company aims to launch more than five blockbuster drugs by 2030 and has established a pipeline sales target above $23 billion by 2035. However, the Ozempic maker faces persistent doubts from investors regarding these long-term goals. Consequently, Novo Nordisk stock has tumbled, falling more steeply than the broader market as leadership works to build market confidence during a capital markets day event.Why it mattersThe pharmaceutical giant is navigating intense competition in